Hyderabad News Desk

DelveInsight Business Research LLP

DelveInsight’s, “Allergic Rhinitis – Pipeline Insight, 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Some of the key Highlights for Allergic Rhinitis 

• The Key Companies working for Allergic Rhinitis include Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals Inc., Revolo Biotherapeutics and many others 
• The Key Therapies working for Allergic Rhinitis include REGN5713-5714-5715, MM09-MG01, and many others 

Got queries? Click here to know more about the Allergic Rhinitis 

Allergic Rhinitis Overview

Allergic rhinitis (AR) is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. It affects one in six individuals and is associated with significant morbidity, loss of productivity, and healthcare costs. Historically, AR was thought to be a disease process of the nasal airway alone. Still, the development of the unified airway theory has classified AR as a component of systemic allergic response, with other associated conditions, such as asthma and atopic dermatitis, sharing an underlying systemic pathology. AR can be classified as either seasonal (intermittent) or perennial (chronic), with approximately 20% of cases being seasonal, 40% perennial, and 40% with features of both

There are approx. 35+ key companies which are developing the therapies for Allergic Rhinitis. The companies which have their Allergic Rhinitis drug candidates in the mid to advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals.

Phases

DelveInsight’s Report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
• Route of Administration

Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Learn more by requesting for sample @ Allergic Rhinitis 

Allergic Rhinitis Key Companies

• Hanmi Pharmaceutical
• Immunotek
• Anhui Palo 
• Alto Pharmaceuticals Inc

And many others 

Allergic Rhinitis Therapies

•  REGN5713-5714-5715
• MM09-MG01

And many others 

Table of Contents

•  Key Insights 
•  Report Introduction 
•  Executive Summary of Allergic Rhinitis 
•  Disease Background and Overview
•  Epidemiology and patient population
•  The United States 
•  EU 5
•  Allergic Rhinitis Emerging Therapies
•  Allergic Rhinitis Market Outlook
•  Market Access and Reimbursement of Therapies
•  Appendix
• Allergic Rhinitis  Report Methodology
• DelveInsight Capabilities
• Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services